Exelixis (EXEL) Other Accumulated Expenses (2010 - 2026)
Exelixis (EXEL) posted quarterly Other Accumulated Expenses of $100.3 million for Q2 2026, down 20.12% year-over-year from $125.6 million in Q2 2025, and down 20.02% quarter-over-quarter from $125.4 million in Q1 2026.
Analysis
Exelixis (EXEL) Other Accumulated Expenses (2010 - 2026) Analysis & Trends
Exelixis' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $100.3 million for Q2 2026.
- In Q2 2026, Other Accumulated Expenses fell 20.12% year-over-year to $100.3 million; the TTM figure through Apr 2026 stood at $100.3 million (down 20.12% YoY), while the FY2026 annual figure was $125.4 million, up 31.96% from the prior year.
- Other Accumulated Expenses for Q2 2026 stood at $100.3 million, down from $125.4 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $125.6 million in Q2 2025, with the low at $63.7 million in Q2 2022.
- The 5-year median for Other Accumulated Expenses is $101.4 million (2025), against an average of $99.0 million.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses soared 55.39% in 2023, then dropped 23.1% in 2024.
- Exelixis' Other Accumulated Expenses stood at $78.9 million in 2022, then jumped by 37.37% to $108.4 million in 2023, then decreased by 11.71% to $95.7 million in 2024, then advanced by 9.3% to $104.6 million in 2025, then retreated by 4.14% to $100.3 million in 2026.
- Business Quant data shows EXEL's Other Accumulated Expenses at $100.3 million in Q2 2026, $125.4 million in Q1 2026, and $104.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 102.66 Mn |
| Apr 3, 2026 | 100.29 Mn |
| Jan 2, 2026 | 125.38 Mn |
| Oct 3, 2025 | 104.62 Mn |
| Jul 4, 2025 | 101.37 Mn |
| Apr 4, 2025 | 125.55 Mn |
| Jan 3, 2025 | 95.01 Mn |
| Sep 27, 2024 | 95.72 Mn |
| Jun 28, 2024 | 103.24 Mn |
| Mar 29, 2024 | 104.29 Mn |
| Dec 29, 2023 | 108.42 Mn |
| Sep 29, 2023 | 124.48 Mn |
| Jun 30, 2023 | 110.70 Mn |
| Mar 31, 2023 | 89.49 Mn |
| Dec 30, 2022 | 78.92 Mn |
| Sep 30, 2022 | 80.11 Mn |
| Jul 1, 2022 | 72.57 Mn |
| Apr 1, 2022 | 63.65 Mn |
| Dec 31, 2021 | 53.37 Mn |
| Oct 1, 2021 | 54.75 Mn |